This Event has Passed
Wednesday, April 15, 2020 - 8:30 AM
to Thursday, April 16, 2020 - 5:00 PM
8:30 AM - 5:00 PM See all dates and Times
http://go.evvnt.com/547466-2?pid=2809
Unite around a sustainable value model for innovation Access is now everybody's business. From clinical through commercial, executives must adjust their strategy to the rapidly changing access environment in the USA.
We need company-wide appreciation of how RWE can determine better value propositions, we must all align to shifting customer desires to focus on early detection and prevention, and we must consider ourselves in alignment or even partnership with payers. Most importantly, everyone must align to the simple premise that the only way medicines improve lives is if patients can actually access them.
For that reason, our agenda contains influencers from a broader group than ever before: patient groups, providers, academia, pharma and industry bodies, we have sourced the ingredients for a revolution in access that delivers a roadmap for sustainable innovation.
Prices:
Pharma Silver Pass: USD 1699.0,
Solution Provider Silver Pass: USD 2199.0
Speakers: Chris Leibman SVP, Value and Access Biogen, Robert W. Dubois CSO and EVP National Pharmaceutical Council, Sarah Emond EVP and COO ICER, Anne Heatherington SVP, Head of Data Sciences Institute Takeda, Matt Portch SVP, Sales and Market Access Sunovion Pharmaceuticals, Rj Lasek Vice President, Commercial Operations Takeda, Scott Howell VP and Head, US Market Access, Pharmaceuticals Novartis, Sonal Bhatia, MD VP, North America Medical Lead, Rare Disease Pfizer, Timothy Paine VP, Pharma Strategy and Relations Fairview Specialty Pharmacy, Jacob Jolly Director, Specialty Pharmacy Strategy and Market Access Vanderbilt University Medical Center, Jay Newman Head of US Marketing and Patient Access Spark Therapeutics, Inc., Mark Trusheim Strategic Director MIT NEWDIGS, Melissa Skelton Senior Director, Ambulatory Pharmacy Services Banner Health, Eric Widdbrodt Renal Evidence Strategy Lead AstraZeneca
We need company-wide appreciation of how RWE can determine better value propositions, we must all align to shifting customer desires to focus on early detection and prevention, and we must consider ourselves in alignment or even partnership with payers. Most importantly, everyone must align to the simple premise that the only way medicines improve lives is if patients can actually access them.
For that reason, our agenda contains influencers from a broader group than ever before: patient groups, providers, academia, pharma and industry bodies, we have sourced the ingredients for a revolution in access that delivers a roadmap for sustainable innovation.
Prices:
Pharma Silver Pass: USD 1699.0,
Solution Provider Silver Pass: USD 2199.0
Speakers: Chris Leibman SVP, Value and Access Biogen, Robert W. Dubois CSO and EVP National Pharmaceutical Council, Sarah Emond EVP and COO ICER, Anne Heatherington SVP, Head of Data Sciences Institute Takeda, Matt Portch SVP, Sales and Market Access Sunovion Pharmaceuticals, Rj Lasek Vice President, Commercial Operations Takeda, Scott Howell VP and Head, US Market Access, Pharmaceuticals Novartis, Sonal Bhatia, MD VP, North America Medical Lead, Rare Disease Pfizer, Timothy Paine VP, Pharma Strategy and Relations Fairview Specialty Pharmacy, Jacob Jolly Director, Specialty Pharmacy Strategy and Market Access Vanderbilt University Medical Center, Jay Newman Head of US Marketing and Patient Access Spark Therapeutics, Inc., Mark Trusheim Strategic Director MIT NEWDIGS, Melissa Skelton Senior Director, Ambulatory Pharmacy Services Banner Health, Eric Widdbrodt Renal Evidence Strategy Lead AstraZeneca
